Table 7.
Prediction of the ADMET profile of EFD.
| Properties | Parameters | EFD |
|---|---|---|
| Absorption | Water Solubility | −6.49 |
| Caco permeability (cm/s) | 1.389 | |
| GI | 100 | |
| Log Kp (Skin permeation) cm/s | −2.716 | |
| P-gp substrate | No | |
| Distribution | BBB | 0.72 |
| CNS permeation (Log PS) | −1.673 | |
| VD (human) | 0.037 | |
| Metabolism | CYP1A2 inhibitor | No |
| CYP2C19 inhibitor | No | |
| CYP2C9 inhibitor | No | |
| CYP2D6 inhibitor | No | |
| CYP3A4 inhibitor | No | |
| Excretion | Total Clearance (log mL/min/kg) | 0.023 |
| Renal OCT2 substrate | No | |
| Toxicity | AMES toxicity | No |
| hERG I inhibitor | No | |
| hERG II inhibitor | No | |
| Hepatotoxicity | No | |
| Skin Sensitization | No | |
| T. Pyriformis toxicity | 0.354 | |
| Minnow toxicity | −2.303 |
(GI) Gastrointestinal, (BBB) Blood-brain barrier, (VD) Volume of distribution, (AMES) Carcinogenic potential test, (hERG) the human Ether-à-go-go-Related Gene.